Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,417 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Completed Phase 2 Interventional Results available

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

NCT05776862
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss, Atrophy, Muscular, Insulin Resistance
Interventions
Ursolic Acid, Strength Training
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 29, 2026, 7:02 AM EDT
Terminated Phase 1 Interventional Results available

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

NCT03666988
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3368715
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Newport Beach, California • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 29, 2026, 7:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Ashwagandha Root Extract on Stress, Anxiety, and Sleep Quality in Adults Experiencing Minority Stress

NCT07441070
View directory record Official record
Conditions
Minority Stress, Psychological Stress, Anxiety
Interventions
Ashwagandha Root Extract, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

NCT04001088
View directory record Official record
Conditions
Menopause
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Lallemand Health Solutions
Industry
Eligibility
40 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 29, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01080222
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety of FXR-450 in Healthy Subjects

NCT00499629
View directory record Official record
Conditions
Healthy
Interventions
FXR 450, placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee

NCT03028870
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
V120083, Naproxen, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
30
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • North Hollywood, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 29, 2026, 7:02 AM EDT
Terminated Phase 2 Interventional Results available

Zonisamide for Heavy Drinkers With Bipolar Disorder

NCT01566370
View directory record Official record
Conditions
Alcohol Use Disorders, Bipolar Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

NCT00842088
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Placebo, HQK-1001
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
8
States / cities
Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

NCT04173494
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib, Placebo to match danazol, Danazol, Placebo to match momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Not applicable Interventional

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

NCT07189442
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
Interventions
L-theanine and paraxanthine, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

NCT00893269
View directory record Official record
Conditions
Marijuana Dependence
Interventions
eszopiclone, Placebo, ramelteon, zolpidem
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

NCT04902105
View directory record Official record
Conditions
Drug Interaction
Interventions
ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 29, 2026, 7:02 AM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

NCT02243202
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin, Phentermine, Matching Placebo to Canagliflozin, Matching Placebo to Phentermine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Phoenix, Arizona • Walnut Creek, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 29, 2026, 7:02 AM EDT
Recruiting Phase 3 Interventional

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

NCT03813407
View directory record Official record
Conditions
Hyperkalaemia
Interventions
Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2), Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3), Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
14
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

NCT04939467
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet
Drug
Lead sponsor
Blade Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

Aquamin and Prevention of Colon Cancer

NCT02647671
View directory record Official record
Conditions
Colonic Cancer
Interventions
Aquamin®, Calcium Carbonate, Placebo
Drug
Lead sponsor
James Varani
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Fluoxetine, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
7 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
51
States / cities
Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 29, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Results available

Secondary Prevention of Venous Thrombo Embolism (VTE).

NCT00329238
View directory record Official record
Conditions
Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 29, 2026, 7:02 AM EDT